The LSU COVID-19 trial will give us a great deal of data on the effect of this is readily translatable to other infections—such as sepsis.

Often called blood poisoning, sepsis is uncontrollable inflammation caused by an overactive bodily response to threats.

In trying to overwhelm the threats, the body’s immune system unwittingly destroys its own vital systems.

In 2019, 50 million people had sepsis worldwide, and 11 million died from it.

While COVID-19 kills approximately 1% of those who contract it, sepsis will kill over 20%.

ELA is uniquely suited to help in the fight against sepsis. It controls inflammation rather than just simply switching it off, which is equally dangerous.

In a series of mouse studies run by the Marie Curie Institute, ELA treatment led to a 20% reduction in sepsis-related death.

This is equivalent to saving over 2 million lives every year.